Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Foltynie

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
The Lancet. Neurology|January 30, 2016
Vocal tics in Tourette's syndromeTom Foltynie
Movement Disorders : Official Journal of the Movement Disorder Society|January 23, 2020
Seeing through the FOG?Tom Foltynie
Brain : a Journal of Neurology|June 6, 2023
Reducing the number of patients needed in disease modifying trials for parkinsonian disordersTom Foltynie
Movement Disorders : Official Journal of the Movement Disorder Society|February 15, 2020
Diabetes, BMI, and Parkinson'sTom Foltynie, Dilan Athauda
Nature Reviews. Neurology|February 20, 2019
Long-term outcomes of deep brain stimulation in Parkinson diseasePatricia Limousin, Tom Foltynie
Movement Disorders Clinical Practice|February 26, 2019
Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies TreatmentTom Foltynie, Dilan Athauda
Neuroimage|July 16, 2013
Understanding DCM: ten simple rules for the clinicianJoshua Kahan, Tom Foltynie
Neuroreport|October 30, 2013
How can we judge the 'long term' outcomes of novel interventions in Parkinson's disease?Zinovia Kefalopoulou, Tom Foltynie
Eclinicalmedicine|July 10, 2020
Not only loud but also intelligibleTom Foltynie, Tim Grover
Journal of Neurology|April 17, 2013
Parkinson's disease: an update on pathogenesis and treatmentTom Foltynie, Joshua Kahan
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
The Lancet. Neurology|January 30, 2016
Vocal tics in Tourette's syndromeTom Foltynie
Movement Disorders : Official Journal of the Movement Disorder Society|January 23, 2020
Seeing through the FOG?Tom Foltynie
Brain : a Journal of Neurology|June 6, 2023
Reducing the number of patients needed in disease modifying trials for parkinsonian disordersTom Foltynie
Movement Disorders : Official Journal of the Movement Disorder Society|February 15, 2020
Diabetes, BMI, and Parkinson'sTom Foltynie, Dilan Athauda
Nature Reviews. Neurology|February 20, 2019
Long-term outcomes of deep brain stimulation in Parkinson diseasePatricia Limousin, Tom Foltynie
Movement Disorders Clinical Practice|February 26, 2019
Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies TreatmentTom Foltynie, Dilan Athauda
Neuroimage|July 16, 2013
Understanding DCM: ten simple rules for the clinicianJoshua Kahan, Tom Foltynie
Neuroreport|October 30, 2013
How can we judge the 'long term' outcomes of novel interventions in Parkinson's disease?Zinovia Kefalopoulou, Tom Foltynie
Eclinicalmedicine|July 10, 2020
Not only loud but also intelligibleTom Foltynie, Tim Grover
Journal of Neurology|April 17, 2013
Parkinson's disease: an update on pathogenesis and treatmentTom Foltynie, Joshua Kahan
Pageof 10